Rituximab-based combination therapy in patients with Waldenström macroglobulinemia: a systematic review and meta-analysis

References

• ManasanchEEKristinssonSYLandgrenOEtiology of Waldenstrom macroglobulinemia: genetic factors and immune-related conditionsClin Lymphoma Myeloma Leuk201313219419710.1016/j.clml.2013.02.00223473950
   PubMed Web of Science ®Google Scholar
• OwenRGTreonSPAl-KatibAClinicopathological definition of Waldenstrom’s macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom’s macroglobulinemiaSemin Oncol200330211011510.1053/sonc.2003.5008212720118
   PubMed Web of Science ®Google Scholar
• SwerdlowSHCampoEPileriSAThe 2016 revision of the World Health Organization classification of lymphoid neoplasmsBlood2016127202375239010.1182/blood-2016-01-64356926980727
   PubMed Web of Science ®Google Scholar
• VijayAGertzMAWaldenstrom macroglobulinemiaBlood2007109125096510310.1182/blood-2006-11-05501217303694
   PubMed Web of Science ®Google Scholar
• LeblondVKastritisEAdvaniRTreatment recommendations from the Eighth International Workshop on Waldenstrom’s macro-globulinemiaBlood2016128101321132810.1182/blood-2016-04-71123427432877
   PubMed Web of Science ®Google Scholar
• BuskeCLeblondVHow to manage Waldenstrom’s macroglobulinemiaLeukemia201327476277210.1038/leu.2013.3623385376
   PubMed Web of Science ®Google Scholar
• TreonSPXuLYangGMYD88 L265P somatic mutation in Waldenstrom’s macroglobulinemiaN Engl J Med2012367982683310.1056/NEJMoa120071022931316
   PubMed Web of Science ®Google Scholar
• TreonSPCaoYXuLYangGLiuXHunterZRSomatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemiaBlood2014123182791279610.1182/blood-2014-01-55090524553177
   PubMed Web of Science ®Google Scholar
• SallesGBarrettMFoàRRituximab in B-cell hematologic malignancies: a review of 20 years of clinical experienceAdv Ther201734102232227310.1007/s12325-017-0612-x28983798
   PubMed Web of Science ®Google Scholar
• GhobrialIMFonsecaRGreippPRInitial immunoglobulin M ‘flare’ after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group StudyCancer2004101112593259810.1002/cncr.2065815493038
   PubMed Web of Science ®Google Scholar
• GertzMAWaldenstrom macroglobulinemia: 2017 update on diagnosis, risk stratification, and managementAm J Hematol201792220921710.1002/ajh.2455728094456
   PubMed Web of Science ®Google Scholar
• ShamseerLMoherDClarkeMPreferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanationBMJ2015350g764710.1136/bmj.g764725555855
   PubMed Web of Science ®Google Scholar
• OwenRGKyleRAStoneMJResponse assessment in Waldenstrom macroglobulinaemia: update from the VIth International WorkshopBr J Haematol2013160217117610.1111/bjh.1210223150997
   PubMed Web of Science ®Google Scholar
• TreonSPHunterZBarnaganARCHOP plus rituximab therapy in Waldenstrom’s macroglobulinemiaClin Lymphoma20055427327715794864
   PubMedGoogle Scholar
• DimopoulosMAAnagnostopoulosAKyrtsonisMCPrimary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamideJ Clin Oncol200725223344334910.1200/JCO.2007.10.992617577016
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJDBranaganARThalidomide and rituximab in Waldenstrom macroglobulinemiaBlood2008112124452445710.1182/blood-2008-04-15085418713945
   PubMed Web of Science ®Google Scholar
• BuskeCHosterEDreylingMThe addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG)Leukemia200923115316110.1038/leu.2008.26118818699
   PubMed Web of Science ®Google Scholar
• TreonSPSoumeraiJDBranaganARLenalidomide and rituximab in Waldenstrom’s macroglobulinemiaClin Cancer Res200915135536010.1158/1078-0432.CCR-08-086219118065
   PubMed Web of Science ®Google Scholar
• IoakimidisLPattersonCJHunterZRComparative outcomes following CP-R, CVP-R, and CHOP-R in Waldenstrom’s macroglobu-linemiaClin Lymphoma Myeloma200991626610.3816/CLM.2009.n.01619362976
   PubMedGoogle Scholar
• TreonSPBranaganARIoakimidisLLong-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemiaBlood2009113163673367810.1182/blood-2008-09-17732919015393
   PubMed Web of Science ®Google Scholar
• TreonSPIoakimidisLSoumeraiJDPrimary therapy of Waldenstrom macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180J Clin Oncol200927233830383510.1200/JCO.2008.20.467719506160
   PubMed Web of Science ®Google Scholar
• GhobrialIMHongFPadmanabhanSPhase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemiaJ Clin Oncol20102881422142810.1200/JCO.2009.25.323720142586
   PubMed Web of Science ®Google Scholar
• RabascioCLaszloDAndreolaGExpression of the human concentrative nucleotide transporter 1 (hCNT1) gene correlates with clinical response in patients affected by Waldenstrom’s macroglobu-linemia (WM) and small lymphocytic lymphoma (SLL) undergoing a combination treatment with 2-chloro-2′-deoxyadenosine (2-CdA) and RituximabLeuk Res201034445445710.1016/j.leukres.2009.07.00219647871
   PubMed Web of Science ®Google Scholar
• GhobrialIMXieWPadmanabhanSPhase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemiaAm J Hematol201085967067410.1002/ajh.2178820652865
   PubMed Web of Science ®Google Scholar
• AgathocleousARohatinerARuleSWeekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemiaBr J Haematol2010151434635310.1111/j.1365-2141.2010.08340.x20880120
   PubMed Web of Science ®Google Scholar
• PeinertSTamCSPrinceHMFludarabine based combinations are highly effective as first-line or salvage treatment in patients with Waldenstrom macroglobulinemiaLeuk Lymphoma201051122188219710.3109/10428194.2010.52432620939696
   PubMed Web of Science ®Google Scholar
• LaszloDAndreolaGRigacciLRituximab and subcutaneous 2-chloro-2′-deoxyadenosine as therapy in untreated and relapsed Waldenstrom’s macroglobulinemiaClin Lymphoma Myeloma Leuk201111113013210.3816/CLML.2011.n.02921454213
   PubMed Web of Science ®Google Scholar
• TedeschiABenevoloGVarettoniMFludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced diseaseCancer2012118243444310.1002/cncr.2630321732338
   PubMed Web of Science ®Google Scholar
• TedeschiARicciFGoldanigaMCFludarabine, cyclophosphamide, and rituximab in salvage therapy of Waldenstrom’s macroglobulinemiaClin Lymphoma Myeloma Leuk201313223123410.1016/j.clml.2013.02.01123490992
   PubMed Web of Science ®Google Scholar
• DimopoulosMAGarcia-SanzRGavriatopoulouMPrimary therapy of Waldenstrom macroglobulinemia (WM) with weekly bortezomib, low-dose dexamethasone, and rituximab (BDR): long-term results of a phase 2 study of the European Myeloma Network (EMN)Blood2013122193276328210.1182/blood-2013-05-50386224004667
   PubMed Web of Science ®Google Scholar
• TreonSPTripsasCKMeidKCarfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenstrom’s macroglobulinemiaBlood2014124450351010.1182/blood-2014-03-56627324859363
   PubMed Web of Science ®Google Scholar
• TedeschiAPicardiPFerreroSBendamustine and rituximab combination is safe and effective as salvage regimen in Waldenstrom macroglobulinemiaLeuk Lymphoma20155692637264210.3109/10428194.2015.101271425651423
   PubMed Web of Science ®Google Scholar
• SouchetLLevyVOuzegdouhMEfficacy and long-term toxicity of the rituximab-fludarabine-cyclophosphamide combination therapy in Waldenstrom’s macroglobulinemiaAm J Hematol201691878278610.1002/ajh.2440527135784
   PubMed Web of Science ®Google Scholar
• RosenthalADueckACA phase 2 study of lenalidomide, rituximab, cyclophosphamide, and dexamethasone (LR-CD) for untreated low-grade non-Hodgkin lymphoma requiring therapyAm J Hematol201792546747210.1002/ajh.2469328230270
   PubMed Web of Science ®Google Scholar
• PaludoJAbeykoonJPDexamethasone, rituximab and cyclophosphamide for relapsed and/or refractory and treatment-naive patients with Waldenstrom macroglobulinemiaBr J Haematol201717919810510.1111/bjh.1482628786474
   PubMed Web of Science ®Google Scholar
• DimopoulosMAZervasCZomasATreatment of Waldenstrom’s macroglobulinemia with rituximabJ Clin Oncol20022092327233310.1200/JCO.2002.09.03911981004
   PubMed Web of Science ®Google Scholar
• TreonSPEmmanouilidesCKimbyEExtended rituximab therapy in Waldenstrom’s macroglobulinemiaAnn Oncol200516113213810.1093/annonc/mdi02215598950
   PubMed Web of Science ®Google Scholar
• GertzMARueMBloodEKaminerLSVesoleDHGreippPRMulticenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98)Leuk Lymphoma200445102047205510.1080/1042819041000171404315370249
   PubMed Web of Science ®Google Scholar
• TreonSPBranaganARHunterZSantosDTournhilacOAndersonKCParadoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom’s macroglobulinemiaAnn Oncol200415101481148310.1093/annonc/mdh40315367407
   PubMed Web of Science ®Google Scholar
• CastilloJJKananSMeidKManningRHunterZRTreonSPRituximab intolerance in patients with Waldenstrom macroglobulinaemiaBr J Haematol2016174464564810.1111/bjh.1379426523929
   PubMed Web of Science ®Google Scholar
• PatelSVKhanDAAdverse reactions to biologic therapyImmunol Allergy Clin North Am201737239741210.1016/j.iac.2017.01.01228366484
   PubMed Web of Science ®Google Scholar
• HongJKimJYAhnHKBone marrow involvement is predictive of infusion-related reaction during rituximab administration in patients with B cell lymphomaSupport Care Cancer20132141145115210.1007/s00520-012-1639-923111943
   PubMed Web of Science ®Google Scholar
• LangDProuseJBarryFEvaluation of the safety and feasibility of rapid rituximab infusionAsia Pac J Clin Oncol201281717510.1111/j.1743-7563.2011.01487.x22369446
   PubMed Web of Science ®Google Scholar
• BuskeCEradatHADiRienzoCGOfatumumab: another way to target CD20 in Waldenstrom’s macroglobulinaemiaLancet Haematol201741e4e510.1016/S2352-3026(16)30163-627914970
   PubMed Web of Science ®Google Scholar
• FurmanRRKastritisEKyrtsonisMCOnce-weekly ofatumumab in untreated or relapsed Waldenstrom’s macroglobulinaemia: an open-label, single-arm, phase 2 studyLancet Haematol201741e24e3410.1016/S2352-3026(16)30166-127914971
   PubMed Web of Science ®Google Scholar
• GavriatopoulouMKastritisEKyrtsonisMCPhase 2 study of ofatumumab, fludarabine and cyclophosphamide in relapsed/refractory Waldenstrom’s macroglobulinemiaLeuk Lymphoma20175861506150810.1080/10428194.2016.123354127724158
   PubMed Web of Science ®Google Scholar
• KastritisEKyrtsonisMCMorelPCompeting risk survival analysis in patients with symptomatic Waldenstrom macroglobulinemia: the impact of disease unrelated mortality and of rituximab-based primary therapyHaematologica201510011e446e44910.3324/haematol.2015.12414926294729
   PubMed Web of Science ®Google Scholar
• KastritisEDimopoulosMADisease control should be the goal of therapy for WM patientsBlood Adv20171252483248510.1182/bloodadvances.201700564529296898
   PubMed Web of Science ®Google Scholar
• DhodapkarMVHoeringAGertzMALong-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003Blood2009113479379610.1182/blood-2008-07-17208018931340
   PubMed Web of Science ®Google Scholar
• DimopoulosMAKastritisEOwenRGTreatment recommendations for patients with Waldenstrom macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood201412491404141110.1182/blood-2014-03-56513525027391
   PubMed Web of Science ®Google Scholar
• BenevoloGNicolosiMSantambrogioEVitoloUCurrent options to manage Waldenstrom’s macroglobulinemiaExpert Rev Hematol201710763764710.1080/17474086.2017.133959628592170
   PubMed Web of Science ®Google Scholar
• YunSJohnsonACOkoloONWaldenstrom macroglobulinemia: review of pathogenesis and managementClin Lymphoma Myeloma Leuk201717525226210.1016/j.clml.2017.02.02828366781
   PubMed Web of Science ®Google Scholar
• GavriatopoulouMTerposEKastritisEDimopoulosMACurrent treatment options and investigational drugs for Waldenstrom’s macroglobulinemiaExpert Opin Investig Drugs201726219720510.1080/13543784.2017.1275561
   PubMed Web of Science ®Google Scholar
• KastritisEDimopoulosMACurrent therapy guidelines for Waldenstrom’s macroglobulinaemiaBest Pract Res Clin Haematol201629219420510.1016/j.beha.2016.08.02327825466
   PubMed Web of Science ®Google Scholar
• AbdallahAOAtrashSMuzaffarJSuccessful treatment of Bing-Neel syndrome using intrathecal chemotherapy and systemic combination chemotherapy followed by BEAM auto-transplant: a case report and review of literatureClin Lymphoma Myeloma Leuk201313450250610.1016/j.clml.2013.03.00223747080
   PubMed Web of Science ®Google Scholar
• SimonLFitsioriALemalRBing-Neel syndrome, a rare complication of Waldenstrom macroglobulinemia: analysis of 44 cases and review of the literature. A study on behalf of the French Innovative Leukemia Organization (FILO)Haematologica2015100121587159410.3324/haematol.2015.13374426385211
   PubMed Web of Science ®Google Scholar
• KastritisEGavriatopoulouMKyrtsonisMCDexamethasone, rituximab, and cyclophosphamide as primary treatment of Waldenstrom macroglobulinemia: final analysis of a phase 2 studyBlood2015126111392139410.1182/blood-2015-05-64742026359434
   PubMed Web of Science ®Google Scholar
• TreonSPYangGHanzisCAttainment of complete/very good partial response following rituximab-based therapy is an important determinant to progression-free survival, and is impacted by polymorphisms in FCGR3A in Waldenstrom macroglobulinaemiaBr J Haematol2011154222322810.1111/j.1365-2141.2011.08726.x21564078
   PubMed Web of Science ®Google Scholar
• BenjaminiOJainPTrinhLSecond cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomesLeuk Lymphoma20155661643165010.3109/10428194.2014.95720325308294
   PubMed Web of Science ®Google Scholar
• LaszloDAndreolaGRigacciLRituximab and subcutaneous 2-chloro-2′-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter studyJ Clin Oncol201028132233223810.1200/JCO.2009.23.631520368573
   PubMed Web of Science ®Google Scholar
• StoneMJBogenSARole of plasmapheresis in Waldenstrom’s macroglobulinemiaClin Lymphoma Myeloma Leuk201313223824010.1016/j.clml.2013.02.01323522642
   PubMed Web of Science ®Google Scholar
• PalSSDammeijerFHendriksRWRole of Bruton’s tyrosine kinase in B cells and malignanciesMol Cancer20181715710.1186/s12943-018-0779-z29455639
   PubMed Web of Science ®Google Scholar
• DimopoulosMATrotmanJTedeschiAIbrutinib for patients with rituximab-refractory Waldenstrom’s macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trialLancet Oncol201718224125010.1016/S1470-2045(16)30632-527956157
   PubMed Web of Science ®Google Scholar
• TreonSPTripsasCKMeidKIbrutinib in previously treated Waldenstrom’s macroglobulinemiaN Engl J Med2015372151430144010.1056/NEJMoa150154825853747
   PubMed Web of Science ®Google Scholar
• MoherDLiberatiATetzlaffJAltmanDGThe PRISMA GroupPreferred reporting items for systematic reviews and meta-analyses: the PRISMA statementPLoS Med200967e100009710.1371/journal.pmed100009719621072
   PubMed Web of Science ®Google Scholar